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A major determinant of cell fate is regulation of cell cycle. Tight regulation of this process is lost during the course
of development and progression of various tumors. The ubiquitin-proteasome system (UPS) constitutes a universal
protein degradation pathway, essential for the consistent recycling of a plethora of proteins with distinct structural
and functional roles within the cell, including cell cycle regulation. High grade tumors, such as glioblastomas have
an inherent potential of escaping cell cycle control mechanisms and are often refractory to conventional treatment.
Here, we review the association of UPS with several UPS-targeted proteins and pathways involved in regulation of
the cell cycle in malignant gliomas, and discuss the potential role of UPS inhibitors in reinstitution of cell cycle
control.
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Malignant gliomas constitute a spectrum of poorly differ-
entiated primary brain tumors of astrocytic or oligo-
dendroglial origin with a marked resistance to treatment,
a high tendency of recurrence and a poor prognosis [1,2].
Deregulation of cell cycle in most cancer cell types, in-
cluding glioma is a critical mechanism of development,
progression, and resistance to treatment [3]. Aberrant
function of critical regulators of the cell cycle generally
results in modification of growth, differentiation and
apoptotic properties of the cell. Knowledge of the regu-
latory mechanisms that govern the function of cell cycle
controllers is critical to enable design of new or use of
already existing inhibitors with the aim of inducing a cell
cycle related anticancer effect.
The ubiquitin-proteasome system (UPS) is long-
known as a cellular tool for the marking and proteo-
lytic degradation of proteins involved in a wide var-
iety of structural and functional roles inside the cell.
The UPS includes the “ubiquitously” expressed 76-
amino acid protein ubiquitin (Ub), the multisubunit
protein organelle 26S proteasome, consisting of one
20S catalytic and two 19S regulatoty subunits, and* Correspondence: pvlacho@med.uth.gr
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distribution, and reproduction in any mediumfinally, a 3-step enzymatic cascade of Ub-activating
(E1), Ub-conjugating (E2) and Ub-ligase (E3) enzymes
which attach ubiquitin to the target protein [4,5].
In cancer, a great number of cellular proteins with
various roles, including cell cycle control, either com-
prise direct targets of an aberrant degradation machinery
or have a close structural or/and functional connection
with abnormal ubiquitin- or ubiquitin like-ligases, deubi-
quitinating enzymes and UPS-regulated signaling factors
and pathways [6-8]. In this context, the involvement of
UPS in cell cycle regulation is critical.Ubiquitination and proteasomal degradation of
glioma cell cycle proteins
The earliest evidence indicative of an association be-
tween the stability of cell cycle proteins and UPS in gli-
omas concerns the cyclin-dependent kinase inhibitor
p27, which was proved to be degraded in a proteasome-
dependent manner [9,10]. p27 is a negative regulator of
cyclin D-Cdk4, cyclin E-Cdk2 and cyclin A-Cdk2, being
involved in G1-S transition, and its expression was
observed to decrease with advancing anaplasia of astro-
cytic tumors. This feature was correlated with and, at
least partially, attributed to increased levels of degrad-
ation activity [9]. This finding is further supported by
evidence of an inverse correlation between levels of p27
and Skp2 (S-phase kinase-associated protein 2), aCentral Ltd. This is an Open Access article distributed under the terms of the
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that promotes G1-S transition through targeting of p27
for degradation. p27 decreased with anaplasia and al-
most disappeared in glioblastomas (GBMs), whereas
Skp2 was absent or poorly expressed in well-differen-
tiated astrocytomas and it was diffusely or focally
expressed in most GBMs [11].
p21 is another cell cycle-related protein target of the
ubiquitin-proteasome pathway in gliomas. Being an estab-
lished Cdk2 inhibitor (and likely Cdk1 and Cdk3 as well),
p21 was found to be dependent on the ubiquitin ligase
APC/CCdc20 (Anaphase Promoting Complex/Cyclosome
and its activator Cdc20) for its proteolytic degradation by
the proteasome in prometaphase [12]. The suggested
model involves a positive feedback loop where Cdk1, by
phosphorylating certain subunits of APC/CCdc20, pro-
motes the activity of APC/CCdc20, consequently triggering
the degradation of p21, resulting in a further activation of
Cdk1. The degradation of p21 via APC/CCdc20 contributes
to the full activation of Cdk1 in early M phase and pre-
vents mitotic slippage during activation of the spindle as-
sembly checkpoint [12]. The APC/CCdc20 regulates the
UPS-dependent degradation of several proteins that drive
the cell cycle, including cyclins A and B, while other APC/
CCdc20 substrates (geminin, survivin, polo and aurora
kinases) or regulators (Emi1, RASSF1A) are overexpressed
in high grade gliomas [13]. p21 is also a transcriptional
target of p53 and a negative regulator of the proteasome-
dependent stability of p53- and Rb [14,15] whose intimate
associations with the UPS are well-established and ana-
lyzed below.
The migration and invasion inhibitor protein (MIIP, also
known as IIp45) was discovered as a negative regulator of
cell migration and invasion in glioma and its expression
was reduced or undetectable in tissue samples obtained
from patients with GBM. At the cellular level, an import-
ant role was revealed for MIIP in the inhibition of glioma-
genesis and attenuation of mitotic transition based on its
association with APC/C activity. MIIP interacts directly
with Cdc20, and this interaction of inhibits APC/
C-mediated degradation of cyclin B1, thereby causing at-
tenuation of mitotic transition and increased mitotic ca-
tastrophe [16]. Thus, loss of MIIP promotes cell cycle
progression and mitotic activity during development and
progression of gliomas.
Cdk1 (also named Cdc2) and cyclin B1 are also targets
of the proteasome as evidenced from a study using gelda-
namycin, a drug interfering with the function of the
chaperone protein Hsp90 (Heat shock protein 90), in gli-
oma cells. Geldamycin promotes proteasome degradation
of client proteins by inhibiting Hsp90 function [17]. In
addition to Cdk1, proteasome-mediated degradation of
kinase chk1 (check point kinase 1), a Cdk1 regulator, is
also promoted by geldanamycin [18].The cyclin A/Cdk2 complex was also demonstrated to
be a proteasome substrate after being tethered to a con-
structed chimeric protein composed of an F-box protein
(TrCP) fused to a cyclin A/Cdc2 inhibitor binding pep-
tide. Moreover, this proteasome-mediated destruction
resulted in massive tumor cell (including glioma) apop-
tosis both in vitro and in vivo. The explanation provided,
was based on unopposed E2F1 (a cell cycle regulatory
transcription factor) activity which is further enhanced
in Rb-deregulated cells [19].
UPS is also involved in the regulation of cyclin D1
protein levels. This is effected through its phosphoryl-
ation by the IKKα (Inhibitor of kappa B kinase alpha),
which in turn drives the protein from nucleus to the
cytoplasm, targeting it for ubiquitination and subsequent
proteolytic degradation by the proteasome [20]. Of note
is that this translocation preceding proteolytic degrad-
ation is favoured by acidic environment [21]. On the
other hand, UPS is also “present” in cyclin D1 upregula-
tion via the UPS-regulated transcription factor NF-κB,
activation of which contributes to cell cycle progression
and prevents differentiating GBM-initiating cells (GICs)
from acquiring a mature postmitotic phenotype [22].
The E2F1 protein, a cellular mediator involved in the
transition from G1 to S phase was found to be degraded
by the proteasome in response to Δ9-tetrahydrocannabinol
treatment of human GBM cells, thus blocking cell cycle
progression and supporting a role for cannabinoids as
anticancer agents [23]. The first report implicating the UPS
in E2F1 regulation had revealed a degradation target se-
quence in a carboxyl-terminal region of E2F1 as well as a
stabilizing role for Rb tumor suppressor protein in this
process [24].
A relatively new cell cycle regulatory protein in malig-
nant astrocytoma, Pescadillo, is subjected to post-
translational modification by SUMO-1 (small ubiquitin-
like modifier, a member of the ubiquitin protein family).
Pescadillo protein expression is upregulated after loss of
p53, contributing to cell cycle progression and prolifera-
tion. This SUMO-1 modification may be important for
protein targeting and protein-protein interactions, al-
though it is probably not involved in a proteolytic con-
trol of the protein-conjugate, as derived from data
obtained from yeast and human cells, in which SUMO-1
conjugates remained unaffected by proteasome inhib-
ition [25].
There are also several implications for an indirect role
of UPS in cell cycle, mediated through the regulation of
stability of the oncoprotein c-Myc, which is a known ac-
tivator of cell cycle acceleration. Interestingly, the DNA-
dependent protein kinase catalytic subunit (DNA-PKcs)
has emerged as a novel modulator of this ubiquitin-
mediated c-Myc proteolysis via Akt /glycogen synthase
kinase 3 (GSK3) pro-survival pathway in human glioma
Figure 1 UPS-dependent regulation of cyclins, Cdks and Cdk inhibitors in GBM.
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relation with cell cycle responses in astrocytoma cell
lines involves a G1 arrest together with inhibition of
DNA synthesis and delay in S phase transition. These
effects emanate from loss of cyclin E and cyclin A pro-
teins accompanied by inhibition of the cyclin D1/Cdk4
complex activity (as evaluated by presence of its active
unphosphorylated target substrate, Rb) via p21 and p57
assembly [27]. Notably, Rb, which plays a key role in
regulation of cell cycle, primarily via interaction with the
E2F family of transcription factors in assembly of active
repressor complexes to negatively regulate expression of
E2F-dependent genes important for cell cycle progres-
sion, is itself a proteasome target protein. This regulation
of Rb protein levels is governed by an Mdm2-mediated
promotion of Rb-20S proteasome subunit interaction
leading to a proteasome-dependent ubiquitin-independent
degradation of Rb [28].
Mutations of the gene PARK2, which encodes an E3
ubiquitin ligase, parkin, is common not only in early-
onset familial Parkinson’s disease but also in cancer, as
they occur in the same domains, and sometimes at the
same residues. The significance of PARK2 mutations in
various cancers, including GBM, lies in the fact that the
subsequent decrease in PARK2’s E3 ligase activity com-
promises its ability to ubiquitinate cyclin E and thereby
results in mitotic instability [29,30]. Parkin expression is
dramatically reduced in glioma cells. Restoration of par-
kin expression promotes G1 phase cell cycle arrest andattenuates the proliferation rate of glioma cells in vitro
and in vivo. Notably, parkin-expressing glioma cells have
reduced levels of cyclin D1, but not cyclin E, and a se-
lective downregulation of Akt serine-473 phosphoryl-
ation and VEGF receptor levels. Reversely, parkin-null
mouse models exhibit increased levels of cyclin D1,
VEGF receptor, and Akt phosphorylation, and divide sig-
nificantly faster when compared with wild-type cells,
with suppression of these changes following parkin re-
introduction. At the clinical level, a prognostic role of
the parkin pathway has emerged from studying the sur-
vival outcome of patients with glioma according to par-
kin status. Parkin expression in GBM patients is
associated with lower grade and improved survival [31].
Regulator of Cullins-1 (ROC1) or Ring Box Protein-
1 (RBX1) is a RING component of SCF (Skp-1, cul-
lins, F-box proteins) E3 ubiquitin ligases implicated in
cell growth and cell cycle progression of GBM. The
latter was shown to be attenuated after ROC1 silen-
cing by siRNA which caused growth inhibition, induc-
tion of senescence, apoptosis and G2/M arrest in U87
GBM cells. Senescence induction was coupled with
DNA damage in p53/p21- and p16/Rb-independent
manners. Apoptosis was associated with accumulation
of Puma (p53 upregulated modulator of apoptosis)
and reduction of Bcl-2, Mcl-1, (Myeloid cell leukemia
sequence 1) and survivin, and G2/M arrest was asso-
ciated with accumulation of 14-3-3sigma and elimin-
ation of cyclin B1 and Cdc2 [32].
Figure 2 UPS-dependent regulation of cell cycle-associated transcription factors in GBM.
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cell cycle arrest and/or apoptosis, whenever indicated as
a response to various stressors, could not be ensured
without the critical involvement of p53, whose levels
and activation within the ARF-Mdm2-p53 axis are under
tight UPS-dependent regulation. Phosphorylation in re-
sponse to genotoxic stimuli, acetylation and deubiquiti-
nation enhance p53 stabilization and activation via
attenuated interaction with Mdm2 and inhibition or re-
versal of ubiquitination. Phosphorylation of the E3-ligase
Mdm2 may either suspend nuclear export of p53 or pro-
mote nuclear translocation of Mdm2 with adverse con-
sequences on p53 stability, depending on the inducing
kinase (ATM signaling stabilizes p53, Akt signalling
destabilizes it). ARF can induce the accumulation of p53
by repressing Mdm2, and all three members of the axis
(ARF, Mdm2, p53) exhibit non-overlapping activities and
participate in autoregulatory feedback loops involving
p53-Mdm2 and p53-ARF doublets [33]. The p53 path-
way plays a crucial role in the development of secondary
GBMs, thought to be derived to the malignant progres-
sion to grade II or III astrocytomas as p53 mutations are
rather common (65 %) in this subtype [34,35]. Amplifi-
cation of Mdm2 is rare but amplification and overex-
pression of MdmX, which is a p53-binding protein with
close homology to Mdm2, has been found in certain ma-
lignant gliomas that have wild-type p53 [36]. Further,
the alternative splicing of Mdm2 has been correlated
with stabilized wild-type p53 in certain human GBM
cells [37]. Newer studies have ascribed a role for merlin,a neurofibromatosis 2 (NF2)-related tumor suppressor in
promotion of p53 stability and activity by inducing
Mdm2 degradation in glioma cells [38]. p53 protection
from Mdm2-mediated degradation is also conferred by
PTEN via inhibition of PI3K/Akt signaling that
promotes Mdm2 nuclear translocation. Furthermore,
activated p53 induces PTEN gene expression, providing
evidence for a positive feedback loop, amplifying
sensitization of glioma cells to chemotherapy that relies
on p53 activity [39]. The process of post-translational
p53 stabilization further involves reversible protein
phosphorylation by a kinase/phosphatase pair. In gen-
eral, phosphorylation of p53 blocks the p53-Mdm2
interaction and thus stabilizes p53 in stressed cells. A
newly identified complex GAS41-PP2Cβ is specifically
required for dephosphorylation of serine 366 on p53 and
this is highly relevant in human glioma given that
GAS41 is frequently amplified in this type of malignancy
[40]. Thus, p53 regulation by UPS in malignant gliomas
is a promising target, in terms of proteasome inhibition,
or ubiquitination-resistant p53 protein transduction
therapy [41]. A stable mutant p53 in which all lysines
were replaced by arginines making it ubiquitination-
resistant was found to be transcriptionally active and to in-
hibit glioma cell proliferation. If transduction efficacy
could be ensured in vivo, a stable ubiquitination-resistant
p53 could become a therapeutically useful intervention in
malignant gliomas.
Most important cell cycle regulators that are intimately
associated with the UPS, either members of the basal cell
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cycle-related transription factors are depicted in Figures 1
and 2, respectively.The role of proteasome inhibition in glioma cell
cycle
The regulation of turnover of many cell cycle effectors by
the UPS in gliomas has led to the consideration of prote-
asome inhibition as a potential modulator of cell cycle ab-
normalities in these tumors. Overall, an illustrative picture
of the changes in cell cycle of GBM cell lines, induced by a
proteasome inhibitor, includes a G2/M cell cycle arrest with
a concomitant decreased percentage of cells in S phase.
This is associated with an increased expression of p21, p27,
cyclin D1 and decreased levels of Cdk2, Cdk4 and E2F4
(member of the E2F family of transcription factors) [42]. As
data from basic and preclinical research continue to accu-
mulate, existing information on the role of UPS in glioma
cell cycle regulation is steadily confirmed by the use of
novel proteasome inhibitors, such as SC68896 and celastrol
[43,44]. Accumulation of G2/M phase-related proteins p21
and p27 was the most prominent cell cycle-related event
after treatment with SC68896. This was accompanied by
caspase cleavage, and sensitization of glioma cells to TRAIL
and CD95L via Upregulation of cell surface expression of
the death receptors DR4 and DR5 [43]. Upregulation of
p21, p27 and cyclin B1 together with downregulation of
Cdk2 were observed with celastrol. Cell cycle arrest was fol-
lowed by proapoptotic Bax and caspase-3 stabilization as
well as reduced levels of antiapoptotic Bcl-2 and XIAP pro-
teins [44]. In addition, a new role has been revealed for the
gamma-secretase inhibitor LLNIe as it was shown to cause
G2/M arrest and subsequent apoptosis in cells with GBM
tumor-initiating cells (TICs) phenotype by inducing prote-
asome inhibition and proteolytic stress [45]. High concen-
trations of ritonavir, an anti-retroviral medication recently
found to be a proteasome inhibitor, induced a cell cycle ar-
rest in the G1 phase followed by apoptosis of GL15 glioma
cells [46].Conclusions
This review was intended to offer an insight to the role
of the UPS in regulation of ubiquitination and stability
of several cell cycle proteins rather than cover all aspects
of cell cycle events being under the control of UPS in
malignant gliomas, as well as of the complexity and ex-
tent of this control. The use of proteasome inhibition as
an anticancer treatment is possibly meaningful in terms
of cell cycle control, and combinations with other agents
with established activity against aberrant cell cycle pro-
gression or under investigation might enable a more effi-
cient strategy for rapidly proliferating tumors such as
malignant gliomas.Competing interests
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